STOCKHOLM – 30 June 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the number of votes in Oncopeptides has changed as a result of a conversion of 209,640 class C shares to 209,640 ordinary shares, to deliver ordinary shares to participants in Oncopeptides’ incentive program Board RSU 2025.
As of today, the total number of shares in Oncopeptides amounts to 395,287,003 shares, of which 381,357,758 are ordinary shares and 13,929,245 are class C shares. As of today, the number of votes in Oncopeptides amounts to 382,750,682.5, and the share capital amounts to SEK 43,920,779.894805.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail:
Cell phone: +46 76 229 38 68
This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-06-30 17:30 CEST.
About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.
Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.
The company was founded in 2000, has about 70 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com
Attachments